Druggability analyses highlighted three candidate genes as top gene targets for cardiovascular disease and four for a neurological disease with repurposing potential, ACHE, CALCRL, MYT1 and TDP1. ACHE is a target of drugs for Alzheimer’s disease including Donepezil and Galantamine, which cause bradycardia as a side effect. Here, CALCRL is linked to early-onset autosomal dominant Alzheimer disease.